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1. Introduction 
This chapter begins with general information on the role of 5’-AMP activated kinase 
(AMPK) in human physiology and the molecular mechanisms that control this kinase. We 
discuss the functions of AMPK in different tissues and their relationship to type 2 diabetes. 
AMPK substrates in different subcellular organelles and compartments are described, and 
we speculate how the localized action of AMPK could help to control type 2 diabetes. Our 
review concludes with future directions that are based on the compartment-specific action 
of AMPK to develop new therapeutic strategies for patients with type 2 diabetes. 
1.1 AMPK activity is critical to cell physiology in different tissues and organs 
AMPK functions as a ser/thr kinase which provides an evolutionary conserved cellular 
energy sensor. This kinase is a focal point for metabolic control in all eukaryotes, where it 
regulates many aspects of physiology (Hardie, 2008a; Kim et al., 2009a; Li & McCullough, 
2010; Lopaschuk, 2008; Ronnett et al., 2009; Steinberg & Kemp, 2009; Zhang, et al., 2009). It 
is well-established that AMPK and its yeast ortholog Snf1 control a large number of 
diverse processes; they include the response to nutrient limitation or other environmental 
changes, transcription, transport across the nuclear envelope, cell growth, cell cycle 
progression, mitosis, cell polarity, development, auto- and mitophagy (Amato et al., 2011; 
Bungard et al., 2010; Egan et al., 2010; Lee et al., 2007; Li & McCullough, 2010; Mirouse et 
al., 2007; Nagata & Hirata, 2009; Narbonne & Roy, 2009; Quan et al., 2007; Steinberg & 
Kemp, 2009; Viollet et al., 2009a; Wang et al., 2010; Witczak et al., 2008). As a result of 
these contributions, AMPK is vital to the function of several organs and tissues in 
metazoans (Fig. 1). 
Owing to its pivotal role in the control of glucose homeostasis, carbohydrate, lipid and 
protein metabolism AMPK is a key player in many human diseases and disorders (Fogarty 
& Hardie, 2010; Lage et al., 2008; Towler & Hardie, 2007; Viollet et al., 2009b). In particular, 
the low activation state of AMPK could contribute to the increase in type 2 diabetes and 
obesity (Hardie et al., 2006). Moreover, as essential regulator of glucose homeostasis and 
lipid metabolism, AMPK has become an important therapeutic target in type 2 diabetes and 
obesity. This is exemplified by metformin and thiazolidinedione derivatives (TZDs); these 
drugs are used for therapeutic intervention in type 2 diabetes and lead to the activation of 
AMPK. 
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Fig. 1. The role of AMPK in different organs and tissues. AMPK controls the physiology of 
multiple organs which are critical to type 2 diabetes, obesity and other metabolic diseases. 
As such, AMPK regulates both anabolic and catabolic pathways as well as the function and 
biogenesis of organelles. See text for details. 
2. Organization and activation of AMPK 
AMPK senses a drop in cellular energy as it is induced by a reduction in glucose availability 
or other metabolic stresses. The overall consequence of AMPK activation is a change in 
metabolism; thus, when the AMP/ATP ratio increases AMPK becomes activated in order to 
rescue the energy balance. As a result of AMPK activation, the cellular metabolism switches 
from anabolic to catabolic processes. This metabolic shift is accomplished by the AMPK-
dependent phosphorylation of multiple targets which are located in different cellular 
organelles and compartments (see below). 
The heterotrimeric enzyme AMPK (Fig. 2; ǂǃǄ) contains one catalytic ǂ subunit that is 
encoded by two genes (ǂ1 and ǂ2). The regulatory ǃ and Ǆ subunits are encoded by two and 
three genes, respectively (Hardie et al., 2006). The two ǃ subunits (ǃ1, ǃ2) can be 
myristoylated and phosphorylated, and these modifications may impact the activation and 
intracellular localization of AMPK (Oakhill et al., 2010; Warden et al., 2001; see below). The Ǆ 
subunits (Ǆ1, Ǆ2, Ǆ3) bind AMP and ATP in a mutually exclusive fashion, this AMP binding 
is important to the activation of the enzyme. The subunit composition of AMPK 
heterotrimers varies in different tissues and can affect the activation of the kinase (Canto & 
Auwerx, 2010; Cheung et al., 2000; Steinberg & Kemp, 2009; Viollet et al., 2010). 
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2.1 Control of AMPK activity by phosphorylation and changes in AMPK concentration 
The importance of AMPK as a key regulator in cellular metabolism requires a tight control of 
the enzyme. The rapid regulation of AMPK activity is based on at least three mechanisms that 
contribute to AMPK activation (Oakhill et al., 2010; Sanders et al., 2007; Shackelford & Shaw, 
2009; Steinberg & Kemp, 2009). (a) The most important step for AMPK activation is the 
phosphorylation of Thr172 of the ǂ subunit which can be modified by the upstream kinases 
LKB1, CaMKKǃ and TAK1 (Fig. 2). Thr172 is phosphorylated when the energy state of the cell 
is low, i.e. when the AMP/ATP ratio rises. Under these conditions, AMP binding to the 
regulatory Ǆ subunit promotes the subsequent Thr172 phosphorylation. LKB1 is the major 
upstream kinase for this event in tissues like skeletal muscle. The effect of AMP binding 
depends on the type of Ǆ subunit (Cheung et al., 2000). Specifically, AMP-binding to Ǆ2 subunits 
leads to the largest increase in AMPK activity. By contrast, a relative small change is observed 
for the Ǆ3 subunit which is mostly synthesized in glycolytic skeletal muscle. Recent data suggest 
that the ǃ subunits also play a crucial role in AMPK activation. It was proposed that ǃ subunit 
myristoylation provides a switch that is a prerequisite for Thr172 phosphorylation (Oakhill et 
al., 2010). (b) Aside from changes in the AMP/ATP ratio, a rise in intracellular Ca2+ 
concentrations triggers Thr172 phosphorylation. This modification is mediated by CaMKKǃ 
and particularly important in tissues where LKB1 is not the predominant kinase for Thr172. At 
present, the role of TAK1 in AMPK activation is not fully understood. (c) AMPK activation can 
be prolonged by preventing the dephosphorylation of Thr172, a process catalyzed by 
phosphatases PP2A and PP2C (Kim et al., 2009a; Nagata & Hirata, 2010).  
 
 
Fig. 2. Organization of AMPK and regulation of kinase activity by phosphorylation. 
AMPK is a heterotrimeric enzyme that is activated by phosphorylation on Thr172 of the ǂ 
subunit.  Several upstream kinases can modify Thr172; they include LKB, CaMKKǃ and 
TAK1. The activity of AMPK can be reduced by different mechanisms. For example, PP2A 
and PP2C mediate the dephosphorylation of phospho-Thr172. In addition, PKC and Akt 
phosphorylate Ser485/491 of the ǂ chain which decreases AMPK activity. Furthermore, 
PKA-dependent modification of Ser173 diminishes AMPK activity. 
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Aside from the dephosphorylation of phospho-Thr172, a negative regulation of AMPK 
involves the phosphorylation of Ser485/491 by PKC and possibly Akt, whereas the 
decline in activity by Ser173 phosphorylation was ascribed to PKA (Djouder et al., 
2010). Such modification on Ser173 may help to fine tune lipid metabolism in adipose 
tissue.  
The tissue-specific regulation of AMPK activity is likely achieved by the combined effects 
of upstream activating kinases, inactivating phosphatases as well as the synthesis and 
degradation of AMPK subunits. For example, LKB1 is particularly important to activate 
AMPK in skeletal muscle, whereas CaMKKǃ is crucial in the brain (Ronnett et al., 2009). 
On the other hand, TNFǂ alters AMPK activation by modulating the synthesis of PP2C 
(Lu et al., 2010; Steinberg et al., 2006). Aside from the rapid control of AMPK activation by 
phosphorylation, changes in the expression of subunit genes or the turnover of AMPK 
subunits can help to fine tune AMPK activity in some tissues (Barry et al., 2010; 
Fukuyama et al., 2007; Hallows et al., 2006; Qi et al., 2008; Niesler et al., 2007; Steinberg et 
al., 2003). 
2.2 Pharmacological compounds and other factors that alter AMPK activity 
Previous work established the essential role of AMPK in the regulation of carbohydrate, 
protein and lipid metabolism; this made AMPK a key target for the treatment of type 2 
diabetes, obesity and metabolic syndrome (Gruzman, Babai & Sasson, 2009; Hardie, 2008b; 
Steinberg & Kemp, 2009; Viollet et al., 2010; Viollet et al., 2009b). Indeed, in a clinical setting 
AMPK activity is altered with the anti-diabetic drug metformin and other biguanides. The 
drug-induced activation of AMPK has important consequences for the patient; among these 
is the improvement of insulin resistance. 
Pharmacological drugs have also been critical to define how AMPK mediates metabolic 
control (see Table 1). These compounds employ a variety of molecular mechanisms that 
culminate in AMPK activation (Gruzman et al., 2009; Hawley et al., 2010; Mantovani & 
Roy, 2011). For example, the kinase can be activated by a rise in the AMP/ATP ratio, 
generation of an AMP mimetic or increase in intracellular Ca2+ concentrations (Hawley et 
al., 2010). Metformin impacts several biological processes that ultimately activate AMPK. 
These include changes in the respiratory chain, increased synthesis of the protein 
deacetylase SIRT1 (which activates LKB1) and activation of TAK1 (Caton et al., 2010; 
Hawley et al., 2002; Hawley et al., 2010; Xie et al., 2006). Phenphormin promotes the 
LKB1-dependent activation of AMPK by inhibiting mitochondrial complex I (Hawley et 
al., 2010). Resveratrol prevents the acetylation and concomitant inactivation of the 
upstream kinase LKB1, this compound also inhibits mitochondrial ATP synthase and may 
increase the concentration of adiponectin (Hawley et al., 2010; Wang et al., 2011). AICAR 
generates the AMP mimetic 5-amino-4-imidazolecarboxamide ribotide (ZMP) and causes 
a drop in cellular ATP and ADP, which leads to AMPK activation (Hawley et al., 2010). 
Aside from drugs that activate AMPK, compound C serves as an ATP-competitive 
inhibitor of AMPK that has been used widely. All of the compounds discussed here are 
established pharmacological tools that alter AMPK activation or enzymatic activity; they 
have been useful for the analysis of AMPK in vitro, in growing cells and in whole animals. 
The following table summarizes how AMPK activity can be affected in vitro, growing 
cells, organs or whole organisms. 
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Compounds, physiological 
processes and stress 
Mode of action and effect on AMPK 
(A) Drugs and other compounds 
AICAR (5-aminoimidazole-
4-carboxamide-1-b-D-ribo-
furanoside) 
Generation of ZMP, which functions as an analog of AMP; 
activation 
Metformin (Biguanide) Reduces mitochondrial ATP production; activation 
Phenformin Inhibition of respiratory chain, activation 
Resveratrol 
Change in ATP synthase activity; prevents acetylation of 
LKB1 via modulation of SIRT1; upregulation of 
adiponectin synthesis and multimerization; activation 
Thiazolidinedione deriva-
tives (TZDs, troglitazone; 
rosiglitazone, pioglitazone) 
Stimulate the expression and secretion of adiponectin; in-
crease in AMP concentration; activation of PPARǄ; AMPK 
activation  
Antimycin A Inhibition of respiratory chain; activation 
Sodium azide Inhibition of respiratory chain; activation 
NO Inhibition of respiratory chain; activation 
Oligomycin Inhibition of ATP synthase; activation 
Dinitrophenol Uncoupler of electron transfer/ATP synthesis; activation 
2-Deoxyglucose Inhibition of glycolysis; activation 
Arsenite Inhibition of TCA cycle; activation 
ǃ-guanadinopropionic acid Creatine analog; increases AMP/ATP ratio;  activation 
A23187 Activation by increase in cytosolic calcium ions 
A769662 Direct AMPK activator 
Compound C 
(dorsomorphin) 
Reversible, ATP-competitive inhibitor 
(B) Hormones, cytokines, physiological processes and environmental stressors 
Insulin Inhibition of AMPK activation; mediated by Akt kinase 
Ghrelin 
Tissue-specific effects; activation in heart and 
hypothalamus; reduced activity in liver and adipose tissue 
Adiponectin Activation by increase in AMP concentration 
Resistin 
Tissue-specific effects; reduction of AMPK activity in 
skeletal muscle 
Leptin 
Tissue-specific effects; activates ǂ2 heterotrimers; 
activation in muscle and fat tissue; reduces activity in 
hypothalamus 
TNFǂ Acute and chronic effects; acute: activation; chronic: 
reduction in activity; increase in PP2C 
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Compounds, physiological 
processes and stress 
Mode of action and effect on AMPK 
IL-6 
Increase in AMP/ATP ratio; activation  (note that IL-6 can 
have different effects on insulin sensitivity) 
CNTF (Ciliary neurotrophic 
factor) 
Tissue-specific effects; activation in muscle; activity 
reduced in hypothalamus 
UCP1, UCP3 
Uncoupling proteins in mitochondria, change in energy 
status; activation 
Reduction in glucose 
availability 
Change in energy status; activation 
Rise in Ca2+ concentration, 
osmotic stress 
CaMKKǃ activation 
Exercise Skeletal muscle contraction; activation 
Heat shock, oxidative stress Environmental stressors; transient activation 
Ischemia/hypoxia, reactive 
oxygen species 
Metabolism/oxidative stress; activation 
Table 1. Modulators of AMPK activity. 
The data in Table 1 are compiled from several publications that describe the molecular 
mechanisms and tissue-specific effects on AMPK activity in detail (Caton et al., 2010; 
Dzamko & Steinberg, 2009; Hawley et al., 2010; Maeda et al., 2001; Nagata & Hirata, 2010; 
Steinberg et al., 2009; Viollet et al., 2010). It should be noted that although in most cases a 
correlation between treatment and changes in AMPK activity has been demonstrated, the 
molecular mechanisms are not always fully understood. For example, hormone or cytokine-
dependent changes in AMP/ATP ratios may be secondary to other signaling events, such as 
changes in cAMP concentrations. For some of the treatments, it has yet to be established 
whether AMPK is essential for the downstream physiological effect. More recent 
experiments with knockout cells and animal  models will help to fill these gaps (Viollet et 
al., 2009a). 
3. AMPK functions in different tissues and organs 
Although AMPK is present in different tissues and organs, the subunit composition varies, 
and changes in cell physiology can also alter the profile of expressed subunits (Mahlapuu et 
al., 2004; Pulinilkunnil et al., 2011; Putman et al., 2007; Quentin et al., 2011; Stapleton et al., 
1996; Turnley et al., 1999). Of particular importance at the cellular, organ and organismal 
level is the ability of AMPK to switch from anabolic to catabolic processes when energy 
supplies are low. AMPK regulates metabolism and other aspects of cell physiology both 
under normal and disease conditions; studies with different cells or tissues emphasize the 
significance of AMPK for cellular metabolism and the response to various forms of stress. 
Thus, AMPK controls several metabolic pathways that are directly relevant to diabetes and 
other metabolic diseases or syndromes (Steinberg & Kemp, 2009; Viollet et al., 2010; Zhang 
et al., 2009). However, AMPK not only provides a sensor for nutrient availability, the kinase 
is also activated by hormonal signals in peripheral tissues and the hypothalamus (Jorda et 
al., 2010; Ronnett et al., 2009). Notably, this signaling in the central nervous system 
contributes to the regulation of food uptake. Research with hepatic, skeletal muscle, adipose, 
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pancreatic and kidney cells is particularly important to our understanding of type 2 diabetes 
as these cell types are crucial to the etiology or pathophysiology of the disease (Fig. 1). In 
general, the consequences of AMPK activation can be divided into acute and long-term 
effects (Mantovani & Roy, 2011; Viollet et al., 2010). Whereas the phosphorylation of key 
enzymes produces a fast downregulation of ATP-consuming metabolic pathways, long-term 
effects involve changes in the expression of target genes that control metabolism. Since 
several recently published excellent reviews covered these topics extensively, Table 2 only 
summarizes the impact of AMPK activation on tissues that are critical to type 2 diabetes.  
 
Tissue or 
cell type 
Physiological process 
Enzyme or process affected by 
AMPK  
Liver 
activation of fatty acid oxidation, 
inhibition of lipogenesis 
inhibition of acetyl-CoA 
carboxylase ACC (Acc1, Acc2) 
reduced cholesterol synthesis HMG-CoA reductase 
stimulation of fatty acid uptake 
CD36 (a fatty acid translocase) 
moves to the plasma membrane 
changes in lipogenesis and glycolysis 
due to reduced concentration of tran-
scriptional regulators SREBP1 (sterol 
response element binding protein-1) 
and ChREBP (carbohydrate response-
element binding protein) 
inhibits ChREBP by 
phosphorylation, reduces the 
transcription of genes encoding 
SREBP1 and ChREBP 
increase in mitochondrial biogenesis 
increased expression of PGC1ǂ 
and other genes required for 
mitochondrial biogenesis 
glycogen synthesis  reduced inhibition of glycogen synthase 
inhibition of gluconeogenesis and 
hepatic glucose production 
changes in the activity, concentra-
tion or localization of key enzymes 
or transcriptional regulators; 
(phosphoenol pyruvate carboxy 
kinase, HNF4; TORC2, p300) 
Skeletal 
muscle 
stimulation of glucose uptake; fusion 
of GLUT4 (glucose transporter) 
containing vesicles with plasma 
membrane 
phosphorylation of AS160 may 
promote trafficking of vesicles; 
increased transcription of GLUT4 
gene by phosphorylation of 
HDAC5 
increase in mitochondrial biogenesis 
increased expression of PGC1ǂ 
and other genes required for 
mitochondrial biogenesis 
increased fatty acid uptake and 
oxidation 
inhibition of ACC 
reduction in protein synthesis 
inhibition of mTOR pathway via 
modification of mTOR, TSC2 and 
eEF2 kinase 
control of glycogen metabolism inactivation of glycogen synthase 
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Tissue or 
cell type 
Physiological process 
Enzyme or process affected by 
AMPK  
Adipose 
tissue 
increase in fatty acid oxidation inactivation of ACC 
inhibition of lipolysis 
phosphorylation of HSL, reduced 
association of HSL with lipid 
droplets 
Pancreas 
inhibition of glucose-induced insulin 
secretion in ǃ cells 
reduced trafficking of vesicles 
containing insulin 
inhibition of transcription of the 
preproinsulin gene in ǃ cells; 
stimulation of glucagon secretion in ǂ 
cells 
molecular mechanisms not fully 
understood 
Heart 
stimulation of glucose uptake by 
translocation of GLUT4 to the plasma 
membrane 
fusion of GLUT4 containing 
vesicles with the plasma 
membrane 
stimulation of glycolysis 
activation of 6-phosphofructo-2-
kinase → enhances  production of 
fructose 2,6-bisphosphate → 
stimulates 6-phosphofructo-1-
kinase 
increase in fatty acid oxidation inactivation of ACC 
control of glycogen metabolism 
contributions of AMPK activity not 
completely understood at the 
molecular level 
Kidney 
ameliorates changes linked to diabetic 
nephropathy 
inhibition of mTOR, inhibition of 
CFTR and other ion channels 
Brain 
food intake; multiple pathways 
affected in the hypothalamus; 
adiponectin, leptin, insulin and 
ghrelin control AMPK 
control of neuropeptide synthesis 
Table 2. AMPK-dependent modulation of cell physiology.  
Some of the tissue-specific reactions regulated by AMPK and relevant to type 2 diabetes are 
listed. A comprehensive description of these processes can be found in several recent 
reviews (Hardie, 2008a; Ix & Sharma, 2010; Lieberthal & Levine, 2009; Steinberg & Kemp, 
2009; Viollet et al., 2009a; Viollet et al., 2010) and original publications (da Silva Xavier et al., 
2003; Leclerc et al., 2011; Takiar et al., 2011; van Oort et al., 2009).  
4. AMPK modulates targets in different subcellular organelles and 
compartments 
4.1 Subcellular distribution of AMPK substrates 
The combination and integration of different subcellular events regulated by AMPK enables 
cells, tissues and organs to coordinate different metabolic pathways in order to achieve and 
maintain the proper energy balance of the whole organism. Fig. 3 depicts established AMPK 
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substrates according to their presence in different subcellular compartments. Table 3 
expands this information and specifies how the AMPK-dependent phosphorylation of 
individual substrates alters their functions. 
It is obvious from Fig. 3 that AMPK phosphorylates a large number of proteins that are 
associated with distinct organelles or subcellular compartments. Cytoplasmic and 
mitochondrial substrates of the kinase include enzymes that are involved in fat, protein, 
glucose and glycogen metabolism. Kinase targets in the plasma membrane consist of ion 
channels, carriers and receptors, whereas other substrates are linked to the function or 
trafficking of intracellular membranes. This includes the transport of vesicles containing the 
glucose transporter GLUT4, because GLUT4 translocation to the plasma membrane is a pre-
requisite for efficient glucose uptake in skeletal muscle and other tissues. AS160 and 
TBC1D1 likely play a role in these processes (Table 3). In the nucleus, the AMPK-mediated 
modification of transcription factors, transcriptional regulators and a subunit of RNA-
polymerase I control the expression of genes that are implicated in specific anabolic and 
catabolic reactions. The phosphorylation of several of these targets is also critical to the 
biogenesis of mitochondria and the assembly of ribosomes.  
 
 
Fig. 3. AMPK affects functions in various cellular compartments and organelles. Examples 
are shown for the proteins that AMPK modifies in distinct sub-cellular locations. Some of 
the substrates are present in multiple compartments. PM, plasma membrane. See text and 
Table 3 for details. 
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Given the diverse types of AMPK substrates and their presence in different cellular 
locations, it is helpful to recapitulate their functions (Table 3). This knowledge is a 
prerequisite to understand how the dynamic association and action of AMPK in different 
compartments will impact downstream events. 
Substrates that have been established for AMPK heterotrimers that contain the ǂ1 or ǂ2 
subunit are shown. For different AMPK substrates the function, effect of AMPK-dependent 
phosphorylation and the major subcellular localization are depicted. For some substrates, 
there are cell-type specific differences, and the effect of AMPK-dependent phosphorylation 
may not be fully understood or controversial. The list of AMPK substrates was compiled 
from PhosphoSitePlus (phosphosite.org). 
 
Substrates 
for 
AMPKα1 
Function 
Effect of phos-
phorylation 
Primary 
intracellular 
localization 
Refe-
rences 
Acc1; 
Subunit of 
acetyl-CoA 
carboxylase, 
ACC 
Carboxylates acetyl-CoA, 
thereby generating 
malonyl-CoA; this step is 
rate-limiting for FA 
biosynthesis. 
inhibition cytoplasm 
Sun et 
al., 2006 
Acc2; 
Subunit of 
acetyl-CoA 
carboxylase, 
ACC 
Carboxylates acetyl-CoA, 
thereby generating 
malonyl-CoA; this step is 
rate-limiting for FA 
biosynthesis. 
inhibition 
mitochondria 
(outer 
mitochondrial 
membrane) 
Reihill et 
al., 2007 
AMPKǂ1 Catalytic subunit of AMPK potential 
autoregulation 
cytoplasm, 
nucleus 
Stein et 
al., 2000 
AMPKǃ1 Regulatory subunit of 
AMPK 
enzymatic 
activity, 
localization 
cytoplasm, 
nucleus 
Warden 
et al., 
2001 
CFTR 
Cystic fibrosis 
transmembrane 
conductance regulator, 
chloride channel 
inhibits PKA-
dependent 
stimulation of 
CFTR 
plasma mem-
brane, ER, 
cytoplasmic 
vesicle; early 
endosome 
King et 
al., 2009; 
Kong-
suphol et 
al., 2009; 
Takiar et 
al., 2011 
ChREBP 
Transcription factor; 
repressor 
inactivation of 
DNA binding 
nucleus, 
cytoplasm 
Kawagu-
chi et al., 
2002 
CK1-ε 
(CK1 
epsilon) 
Ser/thr kinase; member of 
the casein kinase 1 (CK1) 
family; phosphorylates 
mPer2 
increase of 
CK1-ε activity; 
control of 
circadian clock 
cytoplasm, 
nucleus, cell 
junction, 
centrosome 
Um et al., 
2007 
CRY1 
(crypto-
chrome) 
DNA photolyase, regulates 
circadian rhythm 
phosphoryla-
tion leads to 
destabilization 
nucleus, 
mitochondria, 
cytoplasm 
Lamia et 
al., 2009 
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Substrates 
for 
AMPKα1 
Function 
Effect of phos-
phorylation 
Primary 
intracellular 
localization 
Refe-
rences 
CRTC-1 
CREB-regulated 
transcriptional coactivator 
phosphoryla-
tion causes 
cytoplasmic 
retention 
nucleus, 
cytoplasm 
Mair et 
al., 2011 
eEF2K 
(eEF2 
kinase) 
Protein kinase; eEF2K 
modifies and thereby 
inactivates eEF2 
activation of 
kinase activity 
cytoplasm 
Brown et 
al., 2004 
eNOS 
Endothelial nitric oxide 
synthase (constitutive), EC 
1.14.13.39; regulation of 
cytoskeletal 
 reorganization 
activation, 
promotes 
deacetylation 
by SIRT1 
plasma 
membrane, 
Golgi 
Chen et 
al., 2010; 
Sun et 
al., 2006 
GABAB-R1 
GABAB receptor subunit; 
G-protein coupled receptor 
increase in 
receptor func-
tion, promotes 
functional 
coupling to K+ 
channels 
plasma 
membrane, 
ER, dendrite, 
axon, 
postsynaptic 
membrane 
Kura-
moto et 
al., 2007 
GABAB-R2 
GABAB receptor subunit; 
G-protein coupled receptor 
increase in 
receptor func-
tion, promotes 
functional 
coupling to K+ 
channels 
plasma 
membrane, 
ER, dendrite, 
axon, 
postsynaptic 
membrane 
Kura-
moto et 
al., 2007 
GBF1; 
Golgi-
specific 
brefeldin A 
resistance 
factor 
Guanine nucleotide 
exchanger for ARF5; 
mediates ARF5 activation; 
Golgi to ER trafficking 
triggers 
disassembly of 
Golgi 
apparatus 
Golgi 
membrane 
Miya-
moto et 
al., 2008 
GFAT 
glutamine-fructose-6-
phosphate transaminase 1; 
EC 2.6.1.16; regulates 
glucoseflux to hexosamine 
pathway 
1.4 fold 
increase in 
enzymatic 
activity 
cytoplasm 
Li et al., 
2007 
GYS1 
Glycogen synthase; EC 
2.4.1.11 
inhibits enzy-
matic activity 
cytoplasm 
Skurat, et 
al., 2000 
H2B Histone H2B 
activates 
stress-induced 
transcription 
nucleus 
Bungard 
et al., 
2010 
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Substrates 
for 
AMPKα1 
Function 
Effect of phos-
phorylation 
Primary 
intracellular 
localization 
Refe-
rences 
HDAC5 
Histone deacetylase 5; 
EC3.5.1.98; transcriptional 
regulator, cell cycle 
progression, development 
reduced bind-
ing to GLUT4 
promoter → 
enhanced 
GLUT4 expres-
sion 
nucleus 
(cytoplasm) 
McGee et 
al., 2008 
HNF4 
alpha 
Hepatocyte nuclear factor 4 
alpha; transcription factor, 
control of gene expression 
in hepatocytes 
reduced DNA-
binding 
nucleus 
Hong et 
al., 2003 
HSL 
Hormone sensitive lipase; 
EC 3.1.1.79; involved in 
triglyceride lipolysis 
inhibition; 
change in the 
association 
with lipid 
droplets 
cytoplasm, 
lipid droplets 
Garton et 
al. 1989; ; 
Watt et 
al., 2006 
IRS1; 
adaptor 
protein 
Insulin receptor substrate 
1, adaptor protein 
modulation of 
PI3 kinase 
signaling 
cytoplasm 
Jakobsen 
et al., 
2001; 
Tzatsos 
& Tsich-
lis, 2007 
KCNMA1 
iso4; 
ǂ subunit 
of BKCa 
channel 
Potassium channel, acti-
vated in response to mem-
brane depolarization, 
oxygen sensing in carotid 
body 
inhibition of 
potassium 
currents 
integral 
membrane 
protein, 
plasma mem-
brane, axon 
Ross et 
al., 2011 
Kir6.2 
(KCNJ11) 
Potassium channel, voltage 
dependent, inward 
rectifying 
might play a 
role in insulin 
secretion 
plasma 
membrane 
Chang et 
al., 2009 
KNS2 
Kinesin 2; kinesin light 
chain 1, motor protein 
biological role 
of modification 
not known 
cytoplasm, 
microtubules 
McDo-
nald et 
al., 2009, 
2010 
KPNA2, 
importin-
ǂ1 
Adaptor for classical 
nuclear import 
interferes with 
nuclear import 
of HuR 
cytoplasm, 
nucleus, nuc-
lear envelope 
Wang et 
al., 2004 
mTOR 
Ser/thr kinase; EC 2.7.11.1; 
catalytic subunit of 
mTORC1 and mTORC2 
links nutrient 
supply to 
translation 
cytoplasm 
Cheng et 
al., 2004 
NKCC2 
(SLC12A1) 
Electroneutral transporter; 
reabsorption of Na+ and 
Cl¯; controls cell volume 
regulation of 
transporter 
activity 
plasma 
membrane 
Fraser et 
al., 2007 
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Substrates 
for 
AMPKα1 
Function 
Effect of phos-
phorylation 
Primary 
intracellular 
localization 
Refe-
rences 
p27Kip1 
(CDKN4) 
Cyclin-dependent kinase 
inhibitor 1B,  controls cell 
cycle progression at G1 
stabilization of 
p27; linked to 
autophagy 
nucleus 
Liang et 
al., 2007 
p300 
Protein (histone) 
acetyltransferase; 
EC2.3.1.48; transcriptional 
co-activator 
inhibits 
interaction 
with nuclear 
receptors, such 
as PPARǄ 
nucleus 
Yang et 
al., 2001 
p53 
Tumor suppressor, 
transcription factor, cell 
cycle arrest, DNA repair, 
apoptosis 
stabilization of 
p300-p53 inte-
raction; con-
trols cell cycle 
progression 
nucleus 
Dornan 
& Hupp, 
2001 
PFKFB2 
6-Phosphofructo-2-kinase/ 
fructose-2,6-
bisphosphatase 2; EC 
2.7.1.105 or EC 3.1.3.46; 
glycolysis 
activation; 
stimulation of 
glycolysis 
cytoplasm 
Marsin et 
al., 2000 
PFKFB3; 
iPFK2 
similar to PFKFB2; 
inducible in monocytes 
activation cytoplasm 
Marsin et 
al., 2002 
PPP1R3C 
(R5/PTG) 
Regulatory subunit of 
protein phosphatase PP1; 
controls PP1 activity; 
targets PP1 to glycogen; 
stimulation of glycogen 
synthase 
promotes 
ubiquitination 
and thereby 
degradation 
glycogen 
granules 
Vernia et 
al., 2009 
PPP2R5C 
(B56 Ǆ) 
Regulatory subunit of pro-
tein phosphatase PP2A; 
possible role in the regula-
tion and targeting of PP2A 
increases 
PP2A activity 
nucleus, 
chromosomes 
Kim et 
al., 2009b 
Raf1 
Ser/thr kinase; EC 2.7.11.1; 
component of 
Ras→Raf→MEK1/2→ERK
1/2 signaling pathway 
 
cytoplasm, 
plasma 
membrane 
Sprenkle 
et al., 
1997 
Raptor 
Regulation of mTORC1 
(mammalian target of 
rapamycin complex 1); 
functions as scaffold 
inhibition of 
mTORC1; cell 
cycle arrest 
cytoplasm 
Gwinn et 
al., 2008 
Rb 
Retinoblastoma protein; 
regulates cell cycle pro-
gression at G1; functions as 
transcriptional co-regula-
tor; tumor suppressor 
control of brain 
development 
nucleus 
Dasgupta 
& 
Milbrandt, 
2009 
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Substrates 
for 
AMPKα1 
Function 
Effect of phos-
phorylation 
Primary 
intracellular 
localization 
Refe-
rences 
smMLCK 
Smooth muscle myosin 
light chain kinase; ser/thr 
protein kinase; EC2.7.11.18 
reduces 
activity of 
smMLCK 
cytoplasm 
Horman 
et al., 
2008 
TBC1D1 
GTPase activating protein 
Rab family members;  
regulates glucose transport 
induces 
binding to 14-
3-3 proteins 
ER 
Chen et 
al., 2008 
TIF-IA 
Transcription initiation 
factor for RNA-pol I 
reduced rDNA 
transcription 
nucleolus 
Hoppe et 
al., 2009 
TORC2 
(CRTC2) 
Transducer of regulated 
CREB protein 2; 
transcriptional regulator 
phosphoryla-
tion causes 
cytoplasmic 
retention 
nucleus, 
cytoplasm 
Koo et 
al., 2005 
TSC2 
(tuberin) 
Generates heterodimer 
with hamartin (TSC1); 
TSC1/TSC2 functions as 
GTPase activator of Rheb 
enhances TSC2 
activity → 
inhibition of 
mTOR 
cytoplasm 
Inoki, et 
al., 2003 
ULK1 
Ser/thr kinase; EC 2.7.11.1; 
binds to mTORC1 via 
raptor, binding controlled 
by nutrient supply 
control of 
autophagy 
cytoplasm 
Egan et 
al., 2011 
VASP 
Vasodilator-stimulated 
phosphoprotein; actin 
regulator 
impairs endo-
thelial actin 
assembly 
cytoplasm, 
cytoskeleton 
Blume et 
al., 2007 
ZNF692 
(AREBP) 
Transcriptional regulator, 
contains zinc finger 
reduction in 
DNA binding 
nucleus 
Inoue & 
Yamau-
chi, 2006 
 
Substrates 
for 
AMPKα2 
Function 
Effect of phos-
phorylation 
Primary 
intracellular 
localization 
Refe-
rences 
ACC1 
See above description of 
AMPKǂ1 targets  cytoplasm  
AS160 
(TBC1D4; 
Akt 
substrate of 
160k) 
GTPase activating protein 
for Rab; implicated in 
GLUT4 exocytosis in 
skeletal muscle 
not fully 
understood; 
may regulate 
glucose uptake 
cytoplasm 
Eguez et 
al., 2005; 
Treebak 
et al., 
2010 
HAS2 
Hyaluronic acid synthase 2; 
EC 2.4.1.212; integral 
membrane protein 
inhibition of 
enzymatic 
activity 
plasma 
membrane 
Vigetti et 
al., 2011 
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HDAC5 
See above description of 
AMPKǂ1 targets  nucleus  
p53 
See above description of 
AMPKǂ1 targets  nucleus  
PGC1ǂ 
PPAR Ǆ coactivator-1; tran-
scriptional co-activator; 
association with PPARǄ; 
binds to CREB and nuclear 
respiratory factors; controls 
mitochondrial biogenesis 
phosphoryla-
tion alters 
activity as 
transcriptional 
regulator 
nucleus 
Jager et 
al., 2007 
PLD1 
Phospholipase D1 
phophatidylcholine 
specific; EC 3.1.4.4; linked 
to Ras signaling; involved 
in membrane trafficking 
activation of 
enzymatic 
activity 
Golgi, ER 
Kim et 
al., 2010 
Table 3. Substrates of AMPK heterotrimers containing the ǂ1 or ǂ2 subunit 
4.2 Subcellular distribution and trafficking of AMPK 
AMPK is associated with different organelles and subcellular compartments; however, little 
is known about the dynamic nature of this distribution. Analyses of other signaling 
pathways have demonstrated that the subcellular localization of kinases is critical for the 
proper response to extra- and intracellular stimuli, and it is likely that the same scenario 
applies to AMPK. We will therefore briefly review what is currently known about the 
subcellular localization and trafficking of AMPK. 
AMPK is found in the nucleus and cytoplasm which reflects functions for the enzyme in both 
locations (Kodiha et al., 2007; Witczak et al., 2008). Although the kinase is associated with 
multiple compartments, ǂ1 and ǂ2 subunits differ in their nucleocytoplasmic distribution. 
Under normal growth conditions, ǂ1 is predominantly in the cytoplasm, whereas ǂ2 locates to 
both the nucleus and cytoplasm (Salt et al., 1998). It was further shown that the nuclear 
localization sequence (NLS) present in the ǂ2 subunit is required for AMPK nuclear 
translocation (Suzuki et al., 2007), suggesting that the catalytic ǂ subunit is essential for the 
proper intracellular localization of the holoenzyme. Our current model of AMPK trafficking 
proposes that the kinase shuttles between the nucleus and the cytoplasm. Data from our group 
and others support this idea, as they demonstrated that the nuclear carrier Crm1 is essential 
for AMPK export from the nucleus to the cytoplasm (Kazgan et al., 2010; Kodiha et al., 2007). 
How the ǃ subunit impacts the proper targeting of the holoenzyme is at present not entirely 
clear. The ǃ1 subunit can be modified posttranslationally, both by phosphorylation and 
myristoylation, and these modifications were linked to the subcellular targeting of the ǃ1 
subunit (Suzuki et al., 2007; Warden et al., 2001). It was proposed that AMPK concentrates in 
the cytoplasm when the heterotrimeric enzyme contains the ǃ1 subunit (Suzuki et al., 2007). 
However, this model is difficult to reconcile with the fact that both ǃ1 and ǃ2 subunits can 
be detected in the nucleus (Kodiha et al., 2007). Furthermore, recent studies suggest that the 
myristoylation of ǃ1 and ǃ2 subunit is particularly important for AMPK activation, as AMP-
dependent myristoylation provides a switch that triggers Thr172 phosphorylation (Oakhill 
et al., 2010). Although the contribution of ǃ subunits to nuclear and membrane targeting of 
the holoenzyme is not completely understood at this point, the importance of the ǃ subunit 
for glycogen binding is well established (Polekhina et al., 2003). 
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In contrast to the ǂ and ǃ subunits, little is known about the trafficking of AMPK Ǆ subunits. 
In Drosophila, the single Ǆ subunit migrates into the nucleus of the fat body with the onset of 
autophagy during normal development, and a potential NLS was detected in this subunit 
(Lippai et al., 2008). It was speculated that this nuclear accumulation contributes to the 
expression of genes that are necessary for autophagy. 
Several studies support the model that the intracellular distribution of AMPK in human and 
other cells is dynamic. This is particularly important in the context of disease, because the 
distribution of AMPK can be modulated by physiological and environmental stimuli. For 
example, the ǂ2 subunit translocates to the cell nucleus upon exercise or environmental 
stress (Kodiha et al., 2007; McGee et al., 2003), indicating that the adaptation of skeletal 
muscle during exercise or metabolic stress is at least in part mediated by the subcellular 
relocation of AMPK. Examples of the relocation of AMPK ǂ subunits in human cells 
exposed to oxidative stress or depleted for energy are shown in Fig. 4 (Kodiha et al., 2007). 
The relocation of AMPK subunits in response to physiological changes is not restricted to 
the ǂ subunits; our previous experiments demonstrated that AMPK ǃ subunits accumulate 
in the nucleus as well when cells are exposed to oxidative and other forms of stress (Kodiha 
et al., 2007). Moreover, AMPK localization could be regulated by the circadian rhythm. 
Specifically, changes in the expression of AMPK subunits may depend on the circadian 
rhythm; this change in expression will then alter the intracellular distribution of AMPK 
(Lamia et al., 2009). Since these studies were carried out with mice, it has yet to be shown 
whether the same applies to humans. 
 
 
Fig. 4. AMPKǂ concentrates in nuclei when cells are exposed to oxidative stress or depleted 
for energy. HeLa cells were treated with diethyl maleate to induce oxidative stress or with a 
combination of sodium azide and 2-deoxyglucose for energy depletion. The distribution of 
AMPKǂ1 and ǂ2 subunits was examined by indirect immunofluorescence; DNA was 
stained with DAPI (Kodiha et al., 2007). Note that the ǂ-subunits are more concentrated in 
nuclei of stressed cells. Several nuclei are marked with arrowheads. Size bar is 20 μm. 
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Studies from several laboratories, including our group, defined the signals and mechanisms 
that determine the trafficking and intracellular distribution of AMPK. Our work also 
suggested crosstalk between other signaling cascades and the localized action of AMPK 
(Kodiha et al., 2007 and unpublished). Ultimately, such crosstalk will add to the complexity 
of downstream events that are modulated by AMPK. Taken together, previous research 
suggests that AMPK subunits move between different subcellular locations, and it can be 
expected that the compartment-specific actions of the kinase are linked to the physiological 
response of cells and tissues. 
4.3 How does the compartment-specific action of AMPK impact cellular functions that 
are relevant to type 2 diabetes? 
Type 2 diabetes is associated with the increased risk of a growing number of diseases and 
pathologies. This is exemplified by renal nephropathy, myocardial disease, stroke, 
Alzheimer’s and Parkinson’s disease (Almdal et al., 2004; Biessels et al., 2006; Burdo et al., 
2009; Hallows et al., 2010; Hu et al., 2007; Maher & Schubert, 2009; Schernhammer et al., 
2011). Several drugs are currently used in the clinical setting to activate AMPK in patients 
suffering from type 2 diabetes or obesity. However, it should be kept in mind that AMPK 
activation can be beneficial as well as harmful in the ischemic heart, and AMPK activation 
may be linked to neurodegeneration (Lopaschuk, 2008; Spasic, Callaerts & Norga, 2009; 
Thornton et al., 2011; Vingtdeux et al., 2011). Thus, activation of AMPK throughout the 
whole organism or the entire cell of a particular tissue may not always be advantageous. As 
an alternative approach, we put forward the concept of a compartment-specific modulation 
of AMPK action. Since AMPK activation can be damaging in the context of some of the 
complications associated with type 2 diabetes, our approach applies both to the localized 
activation as well as inhibition of the kinase. We believe that the confined action of AMPK 
will provide a better therapeutic approach in the future that could reduce the side-effects of 
AMPK modulators. The simplified model in Fig. 5 summarizes the possible changes of 
cellular functions that will be induced by targeting AMPK in different subcellular 
compartments. 
 
 
Fig. 5. Localized modulations of AMPK activity. The possible changes induced by the 
compartment-specific alteration of AMPK activity are depicted. Note that there are cell-type 
dependent differences for the processes regulated by AMPK. 
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In the past few years, significant progress has been made with the identification of AMPK 
substrates and their links to human disease. As shown in Fig. 3 and Table 3, AMPK modifies 
targets in different subcellular compartments or organelles. We propose that the 
modification of these substrates relies on (a) the amount of active AMPK and (b) the 
intracellular distribution of AMPK. The combination of AMPK activation and subcellular 
localization will then determine the level of phosphorylation of its substrates and the 
subsequent changes in cell physiology. Such changes will affect both the rapid response to 
specific stimuli as well as the long-term modification of metabolism and other processes. In 
the following, we focus on some of the processes that are controlled by AMPK and linked to 
type 2 diabetes or the complications associated with the disease.  
4.3.1 AMPK targets the protein synthesis apparatus in the cytoplasm 
Several of the cytoplasmic substrates of AMPK are essential to promote a fast cellular 
response to changes in nutrient supply. For example, AMPK phosphorylates cytoplasmic 
targets, such as eEF2 kinase and mTOR, which regulate protein translation. AMPK-
dependent modification of these substrates results in downregulation of protein synthesis. 
Under some conditions, it could be desirable to preferentially modulate these processes that 
are associated with cytoplasmic AMPK targets. A possible example of such a scenario is the 
diabetic kidney (Cammisotto et al., 2008; Hallows et al., 2010; Lee et al., 2007; McMahon et 
al., 2009). Diabetes-induced renal hypertrophy correlates with diminished AMPK activity 
and, at the same time, with increased protein synthesis under high glucose conditions 
(Hallows et al., 2010). AICAR and metformin reduce protein synthesis triggered by high 
glucose (Lee et al., 2007), but these compounds also produce effects that are unrelated to 
AMPK activation (Mantovani & Roy, 2011). Thus, stimulating AMPK in the cytoplasm could 
provide a more focused approach to reduce damage in the diabetic kidney. 
4.3.2 AMPK targets associated with the plasma membrane and vesicular trafficking 
Several channels and transporters in the plasma membrane are phosphorylated by AMPK 
and control the secretion of insulin, hyperpolarization of ǃ-cells under low glucose 
concentration and the response to hypoxia (Beall et al., 2010; Chang et al., 2009; Düfer et al., 
2010; Evans et al., 2009; Hallows, 2005; Zheng et al., 2008). Although details of the molecular 
mechanisms are not always clear and in part controversial, altering the AMPK activity at the 
plasma membrane has the potential to modify ǃ-cell function. The same principle could also 
apply to the heart and kidney, where several integral proteins of the plasma membrane are 
modified by AMPK. 
4.3.3 AMPK substrates in the nucleus 
In the nucleus, AMPK directly regulates the transcription of genes that control metabolism 
as well as the biogenesis of mitochondria and ribosomes. As such, AMPK modifies HNF4ǂ, 
HDAC5, p300, histone H2B, the tumor suppressor p53, PGC1ǂ, and TIF-1A (see Fig. 3 and 
Table 3). AMPK-dependent phosphorylation of these targets is critical to alter the 
transcriptional profile, which in turn is necessary to adjust metabolic activities in skeletal 
muscle, heart, liver and adipose tissues in response to changes in glucose availability. It is 
reasonable to assume that the modification of transcription factors and transcriptional 
regulators will rely to a large extent on AMPK in the nucleus. This model is supported by a 
recent study that shows AMPK to move along genes together with the transcriptional 
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machinery (Bungard et al., 2010). Activation of AMPK in the nucleus could enhance the 
effects of AMPK on the transcription of several target genes. One of the possible benefits of 
the activation of nuclear AMPK will be the increase in mitochondrial biogenesis. In the long-
term, this could help to stimulate the oxidation of fatty acids and limit the lipotoxicity that is 
linked to type 2 diabetes (Schrauwen & Hesselink, 2004). 
4.3.4 AMPK targets associated with mitochondria 
Acc2 is associated with mitochondria and important for the synthesis of malonyl-CoA, an 
intermediate of fatty acid biosynthesis. AMPK phosphorylates and thereby inactivates Acc, 
which leads to a reduction in malonyl-CoA concentration. As a consequence, de novo fatty 
acid synthesis is reduced and fatty acid oxidation is upregulated. It is conceivable that the 
localized Acc2 inhibition by AMPK could stimulate CPT-1 (carnitine palmitoyltransferase-1) 
dependent transport of fatty acids into mitochondria for subsequent degradation. This in 
turn could reduce the load of peroxidation products of fatty acids in the cytoplasm and the 
subsequent damage to mitochondria (Schrauwen & Hesselink, 2004). 
5. Development of drugs that alter the compartment-specific activity of AMPK 
In order to modulate AMPK activity in a fashion that is more localized as compared to the 
currently used drugs, a number of questions will have to be addressed. This includes the 
ability to regulate AMPK (a) in different organs or tissues and (b) in specific subcellular 
locations. Oral administration of metformin is believed to preferentially alter liver 
metabolism, whereas TZDs and their derivatives affect adipose tissue, skeletal muscle and 
probably ǃ-cells (Gruzman et al., 2009). One possibility to enhance the tissue-specific action 
of AMPK will rely on the development of drugs that directly bind to AMPK; indeed such 
compounds have been described (Hawley et al., 2010). Since tissue-specific differences in 
AMPK subunits have been established, developing compounds that preferentially interact 
with individual subunits or specific subunit combinations of heterotrimers could provide a 
means to increase the specificity of AMPK action. For example, the Ǆ3 subunit is 
predominantly synthesized in glycolytic skeletal muscle and could therefore serve as a 
target to alter AMPK in this tissue. 
Taking into account differences in AMPK subunits could further be exploited to regulate the 
kinase in different subcellular locations (see section 4.2). Thus, it is believed that the ǂ2 
subunit is more concentrated in the nucleus as compared to the ǂ1 subunit; this difference 
could help to activate mainly nuclear or cytoplasmic pools of the kinase. This line of 
reasoning could be expanded to the posttranslational modifications of the ǃ subunit, as 
phosphorylation and myristoylation of the ǃ subunits are implicated in the subcellular 
distribution of the kinase. 
In addition to taking advantage of the differences in AMPK heterotrimers, developing 
AMPK modulators that accumulate in distinct subcellular compartments will be useful. This 
strategy could be based on the generation of combimolecules with multiple properties 
(Rachid et al., 2007). Combimolecules that combine DNA-binding with AMPK activation 
could enhance the modification of nuclear substrates and thereby alter the gene expression 
profile. On the other hand, such combimolecules could exploit the differences in lipid 
composition of intracellular membranes to control the AMPK-dependent phosphorylation of 
mitochondrial Acc2 or channels residing in the plasma membrane. 
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6. Conclusions 
AMPK and its substrates are critical to the etiology and pathology of type 2 diabetes and 
other metabolic diseases. Several of the current therapeutic regimens for type 2 diabetes 
alter AMPK activity, either by affecting the cellular energy status or the concentration of 
AMPK modulators. More recent studies led to the identification of compounds that directly 
bind AMPK and change its enzyme activity. We propose that the future design of drugs that 
takes into account the dynamic subcellular distribution of the kinase and its substrates will 
help to regulate AMPK not only in different tissues and organs, but also at the subcellular 
level. In the long term this approach will help to fine-tune AMPK action and the 
downstream events that rely on the phosphorylation of its targets. 
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